Safety and immunogenicity of inactivated poliovirus vaccine made from sabin strains: A phase II, randomized, positive-controlled Trial

Journal of Infectious Diseases

Volumn 205, Issue 2, 2012, Pages 237-243

  Liao, Guoyang ^a,b   Li, Rongcheng ^c   Li, Changgui ^d   Sun, Mingbo ^a,b   Li, Yanping ^c   Chu, Jiayou ^a,b   Jiang, Shude ^a,b   Li, Qihan ^a,b  

^a INSTITUTE OF MEDICAL BIOLOGY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; TRIVALENT ORAL POLIOMYELITIS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIARRHEA; DROWSINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; FATIGUE; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; LOW DRUG DOSE; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 2; POLIOMYELITIS VIRUS 3; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; VACCINATION;

ANTIBODIES, VIRAL; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; FEMALE; HUMANS; INFANT; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL;

EID: 84555195090     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir723     Document Type: Article

References (24)

1. World Health Assembly. Global eradication of poliomyelitis by the year2000. Resolution WHA 11.28. Geneva: World Health Organization, 1988.
2. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009; 27:2649-52.
3. Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010; 362:2360-9.
4. World Health Organization. Circulating vaccine-derived poliovirus 2000-2010. www.polioeradication.org/content/general/cvdpv-content. pdf. Accessed 15 July 2011.
5. Update on vaccine-derived poliovirusesdworldwide January 2008-June 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1002-6.
6. Global Polio Eradication Initiative (GPEI). Strategic Plan 2010-2012. 2010. http://www.who.int/mediacentre/factsheets/fs114/en/. Accessed 24 November 2011.
7. World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication. Resolution WHA 61.1. Geneva: 2008.
8. Oliver Wyman. Global post-eradication IPV supply and demand assessment: integrated findings commissioned by the Bill & Melinda Gates Foundation and prepared by Oliver Wyman, Inc. March, 2009. www.oliverwyman.com. Accessed 20 April 2011.
9. World Health Organization. WHO global action plan to minimize poliovirus facility-associated risk in the post eradication/post OPV era. www.polioeradication.org/GAP III WORKING DRAFT-07.pdf. Accessed 20 April 2011.
10. World Health Organization. Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses. 2003 Addendum to the Recommendations for the production and quality control of poliomyelitis vaccine (inactivated) WHO Technical Report Series 2004; Annex 2 No. 926. http://www.who. int/mediacentre/factsheets/fs114/ en/. Accessed 24 November 2011.
11. Neutralization test for polio antibodies WHO recommendations for the production and quality control of poliomyelitis vaccine. 2002. WHO Technical Report Series 2002; Annex 2 No. 910. http://www.who. int/mediacentre/factsheets/ fs114/en/. Accessed 24 November 2011.
12. Chinese State Food and Drug Administration (SFDA). The guidance principle of grade standard for adverse reactions that occur in clinical trial of prevention vaccines. Register no. 493. Beijing, China: SFDA, 2005.
13. Chinese State Food and Drug Administration (SFDA). Technical guidance principle for vaccine clinical trials. Register no. 575. Beijing, China: SFDA, 2004.
14. World Health Organization. Manual for the virological investigation of polio. 1997. WHO/EPI/GEN/97.01. http://www.who.int/mediacentre/factsheets/fs114/ en/. Accessed 24 November 2011.
15. World Health Organization. Recommendations for the production and quality control of poliomyelitis vaccine, oral. 1999. Revised 1999 TRS 904, Annex 1. http://www.who.int/mediacentre/factsheets/fs114/en/. Accessed 24 November 2011.
16. Jiang SD, Pye D, Cox JC. Inactivation of poliovirus with betapropiolactone. J Biol Stand 1986; 14:103-9.
17. Hickling J, Jones R, Nundy N. Improving the affordability of inactivated poliovirus vaccine (IPV) for use in low-and middle-income countries 2010. www.path.org. Accessed 24 November 2011.
18. Kersten G, Hazendonk T, Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 1999; 17:2059-66. (Pubitemid 29172378)
19. Kreeftenberg H, vander Velden T, Kersten G, et al. Technology transfer to new developing country markets. Biologicals 2006; 34:155-8. (Pubitemid 43765774)
20. Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011; 10:635-44.
21. Doi Y, Abe S, Yamamoto H, et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001; 105:163-9.
22. Simizu B, Abe S, Yamamoto H, et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006; 34:151-4.
23. Long L, Jiang SD. Comparison of inactivated poliovirus vaccine made from attenuated and wild strains. Chin J Biol 1992; 5:55-7.
24. Ivanov AP, Dragunsky EM, Chumakov KM, et al. 25-dihydroxyvitamin D3 enhances immune responses to inactivated poliovirus vaccine in mice. J Infect Dis 2006; 193:598-600. (Pubitemid 43202752)